Amolyt Pharma Announces $80 MillionSeries B Financing led by Sectoral Asset Management and Andera Partners

Funds to be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 through IND-enabling activities in acromegaly and further expanding early-stage pipeline

LYON, France, and Cambridge, MA, September 16, 2021 — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company’s July 2019 Series A financing, including LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.

Amolyt plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404. In addition, the company continuesto work to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

“We are very pleased to expand our high-quality syndicate with the addition of these new NorthAmerican and European investors, and we are highly appreciative of the continued support from our existing investors” stated Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma. “This financing will give us the opportunity to further pursue our mission of building a leading rare endocrine and related disease company, and we will continue to work to introduce new and potentially life-changing therapeutics to patients globally.”

The Series B financing follows several recent positive pipeline developments, including the following:

• In September 2021, the company announced completion of the multiple ascending dose (MAD) part of its Phase 1 trial of AZP-3601 for the potential treatment of hypoparathyroidism and will present the results at the 2021 meeting of the American Society for Bone and Mineral Research (ASBMR) on October 1st.
• In September2021, the company announced that it had exercised its option to globally license a portfolio of macrocyclicpeptide growth hormone receptor antagonists (GHRAs) under the terms of there search collaboration agreement with Peptidream announced in December 2020. The identified, optimized drug candidate,AZP-3813, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.
• In May 2021, the company presented positive data from the single ascending dose (SAD) part of its Phase 1 trial of AZP-3601 for the potential treatment of hypoparathyroidismat the 23rdEuropean Congress of Endocrinology (ECE). Data showedthat AZP-3601 induced a long-acting serum calcium response following a single administration in healthy volunteers.